How to Build This Generation's Big Pharma Company
Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery.
In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma company around clinical execution. They discuss Formation Bio’s hub-and-spoke model for acquiring and advancing assets, how AI compresses trial timelines and costs, picking winners, regulatory strategy, and what it would take to move from about 50 approvals a year to many more. They also touch on global competition and why clinical…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.